Author Of 1 Presentation
P0305 - Can We Predict Ocrelizumab Super Responder Status in Relapsing Remitting Multiple Sclerosis Patients? (ID 1903)
Abstract
Background
Ocrelizumab (OCR), an anti-CD20 humanized monoclonal antibody, was approved by the FDA for treatment of relapsing-remitting multiple sclerosis (RRMS) in March 2017. We hypothesize that due to inherent biological variability present in individuals, patients’ response to OCR therapy will vary, with a subset appearing to be super responders (SR) when compared to the remaining population (RP).
Objectives
To categorize the response of patients after initiation of OCR therapy into SR or RP based on the following criteria: 1) rapid improvement in symptom profiles, including mobility, and/or neurological exam findings, 2) relapse free disease course, and 3) MRI stabilization throughout treatment. The SR will be characterized to determine if certain covariates distinguish this group from the RP.
Methods
A retrospective chart review was conducted of patients who had completed at least two courses of OCR therapy by July 2019. Eligible subjects were identified using the electronic health record. Patient demographics and medical history including disease duration and prior disease modifying therapy were collected. Patients were categorized into groups (SR vs RP) based on neurological findings, MRIs, and relapse rates as described above. Covariates including patient demographics and lab values (IgG, IgM, IgA, CD3, CD4, CD8) from the initiation of OCR through duration of treatment were analyzed.
Results
Of the 135 eligible patients, 13 (9.6%) were classified as SR. Of the covariates examined, SR exhibited significantly higher mean IgG levels when initiating OCR (p = 0.0448) and maintained higher IgG levels throughout their treatment (Course 1 p = 0.011, Course 2 p = 0.018). SR were younger, median age of 42 years, compared to the RP, median age of 51 years (p =0.14). SR maintained greater stability in IgM levels than the RP (p = <0.0001). SR were more likely to have been crossed-over over from oral therapies than infusions or injectables (p = 0.02).
Conclusions
At a single site, OCR SR tended to be younger with higher baseline IgG and greater IgG resiliency throughout therapy. Consideration of these factors may be of assistance when assessing a patient for OCR therapy.
Presenter Of 1 Presentation
P0305 - Can We Predict Ocrelizumab Super Responder Status in Relapsing Remitting Multiple Sclerosis Patients? (ID 1903)
Abstract
Background
Ocrelizumab (OCR), an anti-CD20 humanized monoclonal antibody, was approved by the FDA for treatment of relapsing-remitting multiple sclerosis (RRMS) in March 2017. We hypothesize that due to inherent biological variability present in individuals, patients’ response to OCR therapy will vary, with a subset appearing to be super responders (SR) when compared to the remaining population (RP).
Objectives
To categorize the response of patients after initiation of OCR therapy into SR or RP based on the following criteria: 1) rapid improvement in symptom profiles, including mobility, and/or neurological exam findings, 2) relapse free disease course, and 3) MRI stabilization throughout treatment. The SR will be characterized to determine if certain covariates distinguish this group from the RP.
Methods
A retrospective chart review was conducted of patients who had completed at least two courses of OCR therapy by July 2019. Eligible subjects were identified using the electronic health record. Patient demographics and medical history including disease duration and prior disease modifying therapy were collected. Patients were categorized into groups (SR vs RP) based on neurological findings, MRIs, and relapse rates as described above. Covariates including patient demographics and lab values (IgG, IgM, IgA, CD3, CD4, CD8) from the initiation of OCR through duration of treatment were analyzed.
Results
Of the 135 eligible patients, 13 (9.6%) were classified as SR. Of the covariates examined, SR exhibited significantly higher mean IgG levels when initiating OCR (p = 0.0448) and maintained higher IgG levels throughout their treatment (Course 1 p = 0.011, Course 2 p = 0.018). SR were younger, median age of 42 years, compared to the RP, median age of 51 years (p =0.14). SR maintained greater stability in IgM levels than the RP (p = <0.0001). SR were more likely to have been crossed-over over from oral therapies than infusions or injectables (p = 0.02).
Conclusions
At a single site, OCR SR tended to be younger with higher baseline IgG and greater IgG resiliency throughout therapy. Consideration of these factors may be of assistance when assessing a patient for OCR therapy.